Business
HELIX BIOPHARMA CORP. Announces Fiscal 2022 Year-End Results
(TheNewswire) Toronto, Ontario – TheNewswire – November 1, 2022...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"HELIX BIOPHARMA CORP. Announces Fiscal 2022 Year-End Results\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Toronto, Ontario –\n \n \n \n \n TheNewswire – November 1, 2022 -\n \n \n Helix BioPharma Corp.\n \n \n (TSX:HBP), (“\n \n \n Helix\n \n \n ” or the “\n \n \n Company\n \n \n ”), a\nclinical-stage biopharmaceutical company developing unique therapies\nin the field of immuno-oncology based on its proprietary technological\nplatform DOS47, today announced financial results for the 2022 fiscal\nyear ended July 31, 2022.\n \n \n \n \n OVERVIEW\n \n \n \n \n The\n \n \n Company\n \n \n reported\n \n \n a net\n \n \n loss and total comprehensive loss\n \n \n of\n$6,563,000 or $0.04 loss per common share\n \n \n for\n \n \n fiscal\n \n \n 2022\n(2021 - $8,038,000 or $0.06 loss per common share).\n \n \n \n \n Clinical\ndevelopment\n \n \n \n \n LDOS47 in lung cancer\n \n \n \n \n \n \n The Phase I study combination therapy in lung cancer\n(LDOS001) was completed and the final clinical trial report issued in\nDecember 2021. A manuscript was accepted for publication in\n \n \n Journal of Thoracic Oncology\nClinical and Research Reports\n \n \n on September\n2\n \n \n nd\n \n \n ,\n2022. A pre-print can be found here:\nhttps://www.jtocrr.org/article/S2666-3643(22)00132-1/fulltext#relatedArticles.\n \n \n \n \n \n \n The Phase II study of combination therapy in lung\ncancer (LDOS003) was halted in the dose escalation portion of the\nstudy in 2020 at the height of pandemic lockdown and the final\nabbreviated clinical trial report has been further delayed amidst war\nin Ukraine where all subjects were recruited. A final effort is being\nmade in an attempt to retrieve any data that is salvageable and\nconclude the study.\n \n \n \n \n \n \n Another important aspect of the development of the\nLDOS47 platform is the combination with chemo- and/or immuno-therapy,\nthat may boost the utility of the platform. The Company has engaged\nseveral key opinion leaders to evaluate the feasibility of such\ncombinations and aims to develop a develop a roadmap by the second\nquarter of 2022.\n \n \n \n \n \n \n LDOS47 in pancreatic cancer\n \n \n \n \n The Company's Phase I-b/II combination trial in\npancreatic cancer (LDSOS006) continues to recruit patients. We\nrecently applied to the...